TY - JOUR
T1 - Clinical implications of HIV and hepatitis B co-infection in Asia and Africa
AU - Hoffmann, Christopher J.
AU - Thio, Chloe L.
N1 - Funding Information:
CLT has served on an independent expert panel supported by an educational grant from Bristol-Myers Squibb. CJH has no conflicts of interest.
Funding Information:
CJH was supported by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (DK074348). CLT was supported by a grant from the National Institute of Allergy and Infectious Diseases (AI060449).
PY - 2007/6
Y1 - 2007/6
N2 - Hepatitis B virus (HBV) is the leading cause of chronic liver disease and liver-related death worldwide, with the majority of these cases occurring in areas of Africa and Asia where HBV prevalence is high. Many of the countries that are affected by hepatitis B are also affected by a high HIV burden, leading to frequent HIV/HBV co-infection. The consequences of co-infection, including increased liver-related morbidity and mortality, increased hepatitis B viral replication, immune reconstitution to HBV in the setting of antiretroviral therapy, and hepatotoxicity from antiretroviral drugs, are especially important in regions with expanding antiretroviral programmes. Little data, however, are available on HIV/HBV co-infection from regions with high chronic hepatitis B prevalence. This Review discusses the epidemiology, natural history, pathogenesis, and management of HIV/HBV co-infection from these areas. Topics for future research relevant to HIV/HBV co-infection in Africa and Asia are also highlighted.
AB - Hepatitis B virus (HBV) is the leading cause of chronic liver disease and liver-related death worldwide, with the majority of these cases occurring in areas of Africa and Asia where HBV prevalence is high. Many of the countries that are affected by hepatitis B are also affected by a high HIV burden, leading to frequent HIV/HBV co-infection. The consequences of co-infection, including increased liver-related morbidity and mortality, increased hepatitis B viral replication, immune reconstitution to HBV in the setting of antiretroviral therapy, and hepatotoxicity from antiretroviral drugs, are especially important in regions with expanding antiretroviral programmes. Little data, however, are available on HIV/HBV co-infection from regions with high chronic hepatitis B prevalence. This Review discusses the epidemiology, natural history, pathogenesis, and management of HIV/HBV co-infection from these areas. Topics for future research relevant to HIV/HBV co-infection in Africa and Asia are also highlighted.
UR - http://www.scopus.com/inward/record.url?scp=34248596577&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34248596577&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(07)70135-4
DO - 10.1016/S1473-3099(07)70135-4
M3 - Review article
C2 - 17521593
AN - SCOPUS:34248596577
SN - 1473-3099
VL - 7
SP - 402
EP - 409
JO - Lancet Infectious Diseases
JF - Lancet Infectious Diseases
IS - 6
ER -